Monte Rosa Therapeutics, Inc. GLUE EPS (Diluted)
Discontinued — last reported Q1 '26
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s EPS (diluted)?
- Monte Rosa Therapeutics, Inc. (GLUE) reported EPS (diluted) of -$0.45 in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s EPS (diluted) decreased by 178.9% year-over-year, from $0.57 to -$0.45.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s EPS (diluted)?
- Over 3 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s EPS (diluted) has grown at a -46.5% compound annual growth rate (CAGR), from $3.01 to -$0.46.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.